Tempus AI today unveiled validation data for its Immune Profile Score (IPS), demonstrating superior predictive power for patient outcomes on immune checkpoint inhibitors versus established biomarkers. In four independent cohorts encompassing over 1,200 patients with metastatic solid tumors, IPS achieved a combined hazard ratio (HR) of 0.45 for overall survival—outperforming tumor mutational burden, microsatellite instability, and PD-L1 expression. Notably, IPS identified 13% of patients with microsatellite-stable colorectal cancer who experienced a pronounced survival benefit (HR=0.20) when treated with ICI therapy, a subgroup typically overlooked by conventional tests. In rare metastatic solid tumors, 17% were classified as IPS-High despite lacking FDA-approved labels for immunotherapy; these patients showed a median survival advantage with an HR of 0.26 compared to IPS-Low counterparts. The test integrates DNA- and RNA-derived immune and clinical features and is available as an add-on for clinicians ordering Tempus’ xT and xR assays, enabling real-time, data-driven treatment decisions without additional sample collection.